When it comes to new cancer drugs, China has recently shown particular promise in the checkpoint inhibitor segment. This therapy, which supports the immune system’s defense reaction against tumor tissue, is used both as monotherapy and in combination with chemotherapy.
Continue reading now
Get 30 days of free access to the Decision Brief to read these and more quality news every day.
Are you already a guest at the China.Table? Log in now